Research And Markets: Will High Volume Usage Of Hormonal Therapies Make Japan An Important Country In Which To Market Effective, Low Toxicity Drugs?

DUBLIN, Ireland -- Prostate cancer is the most common male malignancy in Western countries. Increasing usage of screening and changes in treatment practice means companies will have to adapt to exploit the market. We have Prostate Cancer Insight details physician opinion of currently available products and disease management practice and what they require in the future.

Research and Markets (http://www.researchandmarkets.com/reports/c12962) has announced the addition of Stakeholder Insight: Prostate Cancer Treatment and Commercial Issues to their offering

The scope of this report is as follows:

--Quantitative treatment data from over 440 physicians: 60 from Japan, France, Germany, Italy, Spain and the UK, and 80 from the US

--Qualitative feedback on key findings and future trends in the treatment of prostate cancer and the management of disease and treatment side effects

--Analysis of leading companies in the prostate cancer market and the commercial challenges and opportunities ahead.

The highlights of this report are as follows

--AstraZeneca is promoting Casodex monotherapy heavily in non-metastatic disease as an alternative to an LHRH agonist. Approval for Casodex monotherapy has been delayed in some markets, but physicians are already prescribing off-label, especially in patients with dementia, a condition that can be exacerbated by the use of LHRH agonists.

--In Japan the volume usage of hormonal drug therapy is far more common as the average age of the patient is well over 70 and so curative treatment is often contraindicated. We believe the high volume usage of hormonal therapies makes this an important country in which to market effective, low toxicity drugs.

Clinical trials have shown the lack of activity of estramustine in hormone refractory prostate cancer, but the drug is still commonly used because of the lack of alternatives. Recent trial results of estramustine in combination with Aventis Taxotere show much greater efficacy and usage of this combination is already significant.

Reasons to Purchase this report:

--Identify hot topics and key issues for practicing prostate cancer specialists the questions they really want answered

--Predict future trends in the treatment of prostate cancer and how to capitalize on forthcoming changes in treatment practice

--Plan product development to fill prostate cancer market niches as defined by practicing physicians

The contents of this report are as follows:

Chapter 1 Executive Summary 4

Chapter 2 Introduction 29

Chapter 3 Screening, Diagnosis And Staging 38

Chapter 4 Treatment Strategy 63

Chapter 5 Side Effects And Supportive Care 136

Chapter 6 Commercial Analysis 170

Chapter 7 Supporting Data 183

Chapter 8 Appendix A 196

Chapter 9 Appendix B: 287

For more information visit http://www.researchandmarkets.com/reports/c12962